Journavx Generic: When Will Generic Suzetrigine Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Journavx Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? December 2040 About 14 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the brand’s protection end? December 2040 Its one listed patent
- Can you buy a generic today? Not yet No company lists one for sale
Dr. Brian Staiger Explains
PharmD, BCPS · Clinical pharmacistGeneric suzetrigine is expected to be available in December 2040, about 14 years away. None is for sale yet.
Why December 2040?
It is when Journavx’s patent 11,834,441 ends. That patent covers the active ingredient, the product’s formulation and a way of using it, and once it ends, generics can go on sale as soon as the FDA approves them. We rate it probable: more likely than not, but it can still move.
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Journavx as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Journavx by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- $201M a yearBig seller
- FDA approved 2025 January 2025 FDA Orange Book
- Patents listed 1 last runs to December 2040 FDA Orange Book
- Pharmacies pay $15.41 per tablet NADAC, October 2026
- Medicare Part D spent $27.3M in 2025, for 25.9K people CMS Part D Spending by Drug
- Medicaid prescriptions 26.6K in the last four reported quarters, $11.2M CMS Medicaid drug utilization, to Q1 2026
Journavx’s Road to a Generic
Journavx has had the market to itself since the FDA approved it in January 2025 (Vertex Pharmaceuticals Inc). Its FDA protection (new chemical entity) runs to January 2030. Its one listed patent runs to December 2040.
The first generic of Journavx is expected in December 2040.
Why that month: patent 11,834,441, on the active ingredient, the product’s formulation and a way of using it, ends then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Journavx Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Journavx’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 11,834,441, which ends in December 2040, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 11,834,441 Sets the expected month of generic availability | The active ingredient; the product’s formulation; a way of using it (U-4125) | December 2040 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New chemical entity NCE | Five years of protection for a medicine whose active ingredient the FDA had never approved before. | January 2030 | Active |
Source: FDA Orange Book, application 219209. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Suzetrigine
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Journavx yet.
Approved by the FDA
Not yet. The FDA has not approved a generic suzetrigine. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic suzetrigine for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Journavx Price: What Pharmacies Pay and What Generics Usually Do
What Pharmacies Pay for Journavx 50 mg tablet
$15.41 per tablet in October 2026.
Hover over or tap anywhere on the chart to see that month’s price.
See the numbers
| Month | Pharmacies paid per tablet |
|---|---|
| October 2026 | $15.41 |
| September 2026 | $15.41 |
| August 2026 | $15.41 |
| July 2026 | $15.41 |
| June 2026 | $14.84 |
| May 2026 | $14.84 |
| April 2026 | $14.84 |
| March 2026 | $14.84 |
| February 2026 | $14.85 |
| January 2026 | $14.85 |
NADAC: the national average price retail pharmacies pay to buy the medicine (CMS survey, updated weekly), the last price of each month for one package. It is not what you pay: that depends on your insurance or discount card.
What a Generic Could Cost
How we estimate it. We start from what pharmacies pay for Journavx today: $15.41 per tablet for Journavx 50 mg tablet in October 2026, from the national NADAC survey. Then we apply the FDA’s finding of how far that price usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Dollar figures apply FDA’s median drops to the $15.41 pharmacies pay per tablet today. An estimate from the pattern, not a price quote: what you pay depends on your insurance or discount card.
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Journavx
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Journavx, before manufacturer rebates.
- $17.2M
- January to March 2026, the latest CMS has posted
For 24,805 people, about $538 per prescription fill - $27.3M
- 2025, the whole year
For 25,894 people, about $608 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $17,206,559 | 24,805 | $538.26 |
| 2025 | $27,269,650 | 25,894 | $608.45 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Journavx only, so no generic is counted in it. What CMS says it is used for: This medication is used for short-term relief of moderate to severe pain. Suzetrigine works by changing how your body feels and responds to pain.
Medicaid Prescriptions by Quarter
26,621 prescriptions in the four quarters to Q1 2026, $11.2M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 10,410 | $4,169,628 |
| Q4 2025 | 7,811 | $3,189,804 |
| Q3 2025 | 5,363 | $2,398,219 |
| Q2 2025 | 3,037 | $1,466,581 |
| Q1 2025 | 138 | $65,875 |
Source: CMS Medicaid State Drug Utilization Data, over Journavx’s own package codes.
Journavx Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 50MG | Tablet | Oral | January 2025 | Prescription reference product |
Source: FDA Orange Book, Vertex Pharmaceuticals Inc. Listed for sale today by Vertex Pharmaceuticals Incorporated and Sportpharm LLC (FDA NDC Directory).
Journavx NDC Codes and Packages
Each Journavx package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 51167-0548-25 | SUZETRIGINE 50 mg/1 tablet, film coated | carton of 5 blister packs of 5 tablets | Vertex Pharmaceuticals Incorporated |
| 51167-0548-30 | SUZETRIGINE 50 mg/1 tablet, film coated | bottle of 30 tablets | Vertex Pharmaceuticals Incorporated |
| 51167-0548-31 | SUZETRIGINE 50 mg/1 tablet, film coated | bottle of 100 tablets | Vertex Pharmaceuticals Incorporated |
| 51167-0548-34 | SUZETRIGINE 50 mg/1 tablet, film coated | carton of 10 blister packs of 10 tablets | Vertex Pharmaceuticals Incorporated |
| 85766-0243-01 | SUZETRIGINE 50 mg/1 tablet, film coated | bottle of 100 tablets | Sportpharm LLC |
| 85766-0243-20 | SUZETRIGINE 50 mg/1 tablet, film coated | bottle of 20 tablets | Sportpharm LLC |
| 85766-0243-30 | SUZETRIGINE 50 mg/1 tablet, film coated | bottle of 30 tablets | Sportpharm LLC |
| 85766-0243-99 | SUZETRIGINE 50 mg/1 tablet, film coated | carton of 10 blister packs of 10 tablets | Sportpharm LLC |
Source: the FDA NDC Directory, current listings only. Only packages sold under Journavx’s own FDA approval (NDA 219209) are listed, never a generic. Some codes belong to companies that repackage Journavx: it is the same medicine in a different package.
What a Generic Journavx Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Journavx as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Journavx”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Journavx
Is there a generic for Journavx right now?
No. As of October 9, 2026 no generic suzetrigine is listed for sale in the FDA NDC Directory.
When will Journavx go generic?
December 2040 is the expected month, and that is probable but not certain. It is when Journavx’s patent 11,834,441 ends. That patent covers the active ingredient, the product’s formulation and a way of using it, and once it ends, generics can go on sale as soon as the FDA approves them.
Will generic suzetrigine be the same as Journavx?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Journavx?
Not yet. The FDA Orange Book lists no approved generic version of Journavx.
When does the Journavx patent expire?
One patent is listed for Journavx in the FDA Orange Book; it runs to December 2040. The one behind the expected month is patent 11,834,441, which ends in December 2040. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (December 2040) weighs all of that.
How much does Journavx cost now?
Pharmacies paid about $15.41 per tablet for Journavx 50 mg tablet in October 2026, by the national survey of what pharmacies pay (NADAC). That is the pharmacy’s cost, not your price: what you pay depends on your insurance or discount card.
Changes to This Projection
- First generic expected December 2040 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- TybostCobicistat2029 to 2030
- ZoryveRoflumilast2033 to 2034
- CobenfyTrospium Chloride and Xanomeline Tartrate2036 to 2037
- MiplyffaArimoclomol Citrate2036 to 2037
- Gvoke HypoPenGlucagonApril 2036
- RasonqueDaraxonrasibDuring 2041
About Journavx
- Generic name suzetrigine
- How it is taken By mouth
- Company Vertex Pharmaceuticals Inc
- More drugs Brand-name drugs starting with J
- Have a question? A pharmacist answers, free. Ask about Journavx
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, NADAC (CMS), CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.